Roivant Sciences Ltd. (NASDAQ:ROIV) Holdings Lessened by Corbin Capital Partners L.P.

Corbin Capital Partners L.P. reduced its holdings in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) by 69.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 46,641 shares of the company’s stock after selling 104,245 shares during the period. Roivant Sciences comprises 0.9% of Corbin Capital Partners L.P.’s portfolio, making the stock its 9th largest holding. Corbin Capital Partners L.P.’s holdings in Roivant Sciences were worth $552,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the business. Teacher Retirement System of Texas grew its position in shares of Roivant Sciences by 18.2% during the 4th quarter. Teacher Retirement System of Texas now owns 109,531 shares of the company’s stock valued at $1,296,000 after acquiring an additional 16,891 shares during the period. Xponance Inc. lifted its position in Roivant Sciences by 5.6% during the fourth quarter. Xponance Inc. now owns 49,319 shares of the company’s stock valued at $583,000 after purchasing an additional 2,607 shares in the last quarter. Monimus Capital Management LP bought a new stake in Roivant Sciences during the fourth quarter valued at about $1,621,000. Monaco Asset Management SAM increased its position in Roivant Sciences by 35.0% in the fourth quarter. Monaco Asset Management SAM now owns 135,000 shares of the company’s stock worth $1,597,000 after buying an additional 35,000 shares in the last quarter. Finally, Commonwealth Equity Services LLC raised its stake in shares of Roivant Sciences by 24.2% in the fourth quarter. Commonwealth Equity Services LLC now owns 19,588 shares of the company’s stock worth $232,000 after buying an additional 3,813 shares during the period. 64.76% of the stock is currently owned by institutional investors.

Insider Activity at Roivant Sciences

In other news, Director Sciences Ltd. Roivant acquired 16,845,010 shares of the business’s stock in a transaction dated Monday, January 13th. The stock was purchased at an average price of $20.00 per share, for a total transaction of $336,900,200.00. Following the completion of the transaction, the director now directly owns 96,650,341 shares in the company, valued at approximately $1,933,006,820. This trade represents a 21.11 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Rakhi Kumar sold 227,500 shares of Roivant Sciences stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $10.43, for a total value of $2,372,825.00. Following the completion of the sale, the chief accounting officer now directly owns 163,264 shares in the company, valued at $1,702,843.52. This trade represents a 58.22 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 1,875,586 shares of company stock valued at $21,491,661. Corporate insiders own 7.90% of the company’s stock.

Roivant Sciences Trading Up 0.3 %

NASDAQ:ROIV opened at $10.97 on Friday. The stock has a 50-day moving average price of $10.78 and a 200 day moving average price of $11.48. The stock has a market capitalization of $7.83 billion, a P/E ratio of -73.13 and a beta of 1.26. Roivant Sciences Ltd. has a 12-month low of $9.93 and a 12-month high of $13.06.

Roivant Sciences (NASDAQ:ROIV) last announced its quarterly earnings data on Monday, February 10th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.04. Roivant Sciences had a negative net margin of 119.54% and a negative return on equity of 14.05%. On average, research analysts predict that Roivant Sciences Ltd. will post -0.92 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on ROIV shares. HC Wainwright reiterated a “buy” rating and set a $18.00 price objective on shares of Roivant Sciences in a research note on Tuesday, February 11th. Cantor Fitzgerald raised shares of Roivant Sciences to a “strong-buy” rating in a report on Tuesday, March 4th. One research analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $18.08.

Roivant Sciences Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.